Novavax | NVAX - Operating Expenses


Novavax reported $126.2M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Adma Biologics USD 76.41M 6.8M Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Cassava Sciences USD 13.55M 1.69M Dec/2025
Geron USD 58.8M 2.31M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025